326030 - SK biopharmaceuticals Co., Ltd.

326030 Summary

Biopharma

Stock Price & Overview

₩86,600 +200 (+0.23%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩86,600 ≈ US$62 · Market cap ₩6.8tn (≈ $4.8bn)

326030 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	706.7	547.6	354.9	246.2	418.6	26.0	123.9	1.1
Cost of Revenue	42.9	43.1	34.1	37.8	22.3	2.0	0.5	—
Gross Profit	663.8	504.5	320.8	208.4	396.3	24.0	123.3	1.1
Selling, General & Administrative	459.9	408.2	358.3	339.5	301.4	263.5	202.6	140.2
Operating Income	203.9	96.3	-37.5	-131.1	95.0	-239.5	-79.3	-139.1
Finance Income	35.8	51.5	35.4	35.2	21.0	6.9	5.7	2.2
Finance Costs	50.6	44.9	35.3	35.7	9.6	6.7	3.3	0.8
Pretax Income	150.9	72.6	-43.9	-142.5	71.3	-239.9	-84.5	-137.6
Income Tax Expense	-102.4	-154.4	-8.5	-3.0	6.4	7.5	-12.9	0.6
Net Income	253.3	227.0	-35.4	-139.4	64.8	-247.4	-71.5	-138.1
Total Comprehensive Income	252.3	253.0	-34.8	-127.6	65.1	-253.4	-71.7	-138.6

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Assets	1.20	1.04	0.72	0.66	0.64	0.50	0.14	0.10
Current Assets	0.68	0.65	0.49	0.49	0.47	0.43	0.10	0.08
Cash & Cash Equivalents	0.31	0.32	0.24	0.10	0.23	0.06	0.05	0.07
Inventories	0.10	0.11	0.10	0.09	0.05	0.02	0.01	0.00
Trade Receivables	0.23	0.17	0.11	0.06	0.06	0.01	0.00	—
Non-current Assets	0.52	0.39	0.23	0.18	0.17	0.07	0.04	0.01
Property, Plant & Equipment	0.01	0.01	0.01	0.02	0.02	0.02	0.03	0.01
Intangible Assets	0.05	0.03	0.03	0.02	0.02	0.02	0.00	0.00
Total Liabilities	0.37	0.46	0.40	0.35	0.20	0.12	0.15	0.04
Current Liabilities	0.30	0.40	0.24	0.16	0.15	0.07	0.15	0.03
Non-current Liabilities	0.08	0.07	0.16	0.18	0.05	0.05	0.01	0.01
Total Equity	0.83	0.57	0.32	0.32	0.44	0.38	-0.01	0.06
Share Capital	0.04	0.04	0.04	0.04	0.04	0.04	0.03	0.03
Retained Earnings	-0.35	-0.62	-0.86	-0.83	-0.69	-0.75	-0.50	-0.43

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Cash from Operating Activities	176.3	94.9	-94.2	-159.9	-92.9	-210.7	-81.3	-141.3
Cash from Investing Activities	-35.4	-10.9	225.3	-95.7	259.0	-318.7	-39.5	39.5
Purchase of Property, Plant & Equipment	6.9	1.4	2.4	4.9	4.3	11.0	13.2	1.4
Cash from Financing Activities	-156.7	-4.5	6.6	134.9	-4.6	540.9	97.2	150.0
Net Change in Cash	-15.8	79.5	137.7	-121.9	166.6	8.2	-23.2	49.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	247.4	227.9	194.4	191.7	176.3	144.4	163.0	136.6	134.0	114.0
Cost of Revenue	15.0	14.3	15.0	7.5	9.9	10.5	5.9	16.5	8.7	11.9
Gross Profit	232.4	213.6	179.4	184.2	166.4	133.9	157.1	120.1	125.3	102.0
Selling, General & Administrative	135.3	123.8	133.1	114.1	104.5	108.2	116.5	100.7	99.2	91.7
Operating Income	97.1	89.8	46.3	70.1	61.9	25.7	40.7	19.3	26.0	10.3
Finance Income	11.2	18.7	8.4	7.6	11.6	8.3	22.8	5.3	11.0	12.4
Finance Costs	7.1	14.2	12.1	4.4	25.3	8.8	16.9	9.2	9.1	9.6
Pretax Income	93.4	100.0	33.8	62.1	34.7	20.3	31.5	9.5	23.8	7.8
Income Tax Expense	8.3	-2.8	-99.0	-9.3	5.2	0.7	-154.9	3.2	-0.8	-1.9
Net Income	85.1	102.7	132.7	71.4	29.5	19.6	186.4	6.3	24.6	9.7
Total Comprehensive Income	89.7	112.1	136.8	75.4	22.6	17.5	—	—	—	—

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	1.42	1.32	1.20	1.03	0.95	1.00	1.04	0.78	0.82	0.79
Current Assets	0.88	0.78	0.68	0.64	0.58	0.61	0.65	0.55	0.59	0.56
Cash & Cash Equivalents	0.38	0.31	0.31	0.25	0.22	0.27	0.32	0.27	0.28	0.29
Inventories	0.10	0.09	0.10	0.10	0.11	0.12	0.11	0.11	0.13	0.11
Trade Receivables	0.31	0.29	0.23	0.23	0.18	0.17	0.17	0.14	0.14	0.12
Non-current Assets	0.54	0.54	0.52	0.39	0.38	0.40	0.39	0.22	0.23	0.24
Property, Plant & Equipment	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.04	0.05	0.05
Intangible Assets	0.05	0.05	0.05	0.03	0.03	0.03	0.03	0.03	0.02	0.03
Total Liabilities	0.40	0.39	0.37	0.34	0.34	0.41	0.46	0.41	0.45	0.45
Current Liabilities	0.32	0.31	0.30	0.26	0.26	0.33	0.40	0.34	0.36	0.36
Non-current Liabilities	0.07	0.08	0.08	0.08	0.08	0.08	0.07	0.07	0.09	0.10
Total Equity	1.02	0.93	0.83	0.69	0.61	0.59	0.57	0.37	0.37	0.34
Share Capital	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04
Retained Earnings	-0.16	-0.25	-0.35	-0.49	-0.57	-0.60	-0.62	-0.81	-0.82	-0.85

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	78.1	17.9	87.0	65.4	-3.4	27.3	56.9	22.5	-6.8	22.4
Cash from Investing Activities	-5.6	-7.1	-29.7	-1.9	-2.3	-1.5	-2.4	-13.2	1.8	2.9
Purchase of Property, Plant & Equipment	0.8	1.4	4.3	1.3	1.2	0.1	0.6	0.4	0.3	0.1
Cash from Financing Activities	-2.0	-8.2	-1.8	-26.7	-51.6	-76.7	-1.1	-26.0	-1.1	23.7
Net Change in Cash	70.6	2.6	55.5	36.9	-57.2	-50.9	53.1	-18.8	-4.6	49.8

Consolidated (CFS), from DART. 8 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

326030 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	706.7	+29.1%	+42.1%	+93.6%	—
Operating income	203.9	+111.7%	—	—	—
Net income	253.3	+11.6%	—	—	—
EPS	₩3,234	+11.6%	—	—	—
Operating cash flow	176.3	+85.8%	—	—	—
Shareholders' equity	826.3	+44.0%	+37.7%	+16.9%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

326030 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	93.9%	92.1%	90.4%	84.7%	94.7%	92.4%
Operating margin	28.9%	17.6%	-10.6%	-53.2%	22.7%	-921.2%
Net margin	35.8%	41.4%	-10.0%	-56.6%	15.5%	-951.6%
Return on equity	36.2%	50.7%	-11.1%	-36.7%	15.8%	-135.2%
Return on assets	22.7%	25.8%	-5.1%	-21.3%	11.3%	-77.4%
Operating cash flow / revenue	25.0%	17.3%	-26.5%	-65.0%	-22.2%	-810.5%
Capex / revenue	1.0%	0.3%	0.7%	2.0%	1.0%	42.4%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 326030

Symbol	Last Price
128940Hanmi Pharm. Co., Ltd.	₩473,500 +2.8%
000100Yuhan Corporation	₩81,400 +0.0%
028300HLB Co., Ltd.	₩33,750 +2.9%
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.